Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 808 • 2012 ACR/ARHP Annual Meeting
Power Doppler Is Predictive of Treatment Failure in Early Rheumatoid Arthritis Patients: A One Year Follow-up Study
Karine R. Luz¹, Rita N.V. Furtado¹, Marcelo M. Pinheiro², Giovanna S. Petterle¹ and Jamil Natour¹, ¹Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil, ²Brazilian Registry of Spondyloarthritis, São Paulo, Brazil
Background/Purpose: It is known that ultrasound (US) is a useful test to monitor rheumatoid arthritis (RA) patients. However, to date, no study has shown the…
Abstract Number: 351 • 2012 ACR/ARHP Annual Meeting
Prospective Follow-up of Tocilizumab Treatment in 764 Patients with Refractory Rheumatoid Arthritis: Tolerance and Efficacy Data From the French Registry Regate (REGistry –RoAcTEmra)
Jacques Morel¹, Marie-Odile Duzanski², Thomas Bardin³, Alain G. Cantagrel⁴, Bernard Combe⁵, Maxime Dougados⁶, Rene-Marc Flipo⁷, Jacques-Eric Gottenberg⁸, Xavier Mariette⁹, Martin Soubrier¹⁰, Olivier Vittecoq¹¹, Alain Saraux¹², Thierry Schaeverbeke¹³ and Jean Sibilia¹⁴, ¹Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ²Service Pharmacie - Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ³Rheumatology, Hôpital Lariboisière, Paris, France, ⁴Dept of Rheumatology, Centre Hospitalier Universitaire de Toulouse, Toulouse, France, ⁵Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁶Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁷Rheumatology, Hopital R Salengro CHRU, Lille, France, ⁸Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ¹⁰Rheumatology, CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ¹¹Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, ¹²Rhumatologie, CHU de la Cavale Blanche, Brest Cedex, France, ¹³Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ¹⁴Rhumatologie, CHU Hautepierre, Strasbourg, France
Background/Purpose: To assess tolerance and safety of rheumatoid arthritis (RA) treatment by tocilizumab (TCZ) in real life Methods: The French Society of Rheumatology and the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.